1. Home
  2. CLPR vs EQ Comparison

CLPR vs EQ Comparison

Compare CLPR & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clipper Realty Inc.

CLPR

Clipper Realty Inc.

HOLD

Current Price

$3.49

Market Cap

54.7M

Sector

Real Estate

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$1.52

Market Cap

57.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLPR
EQ
Founded
2015
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.7M
57.8M
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
CLPR
EQ
Price
$3.49
$1.52
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
78.0K
814.7K
Earning Date
02-13-2026
11-13-2025
Dividend Yield
11.28%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$154,179,000.00
$4,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.90
N/A
52 Week Low
$3.31
$0.27
52 Week High
$5.35
$2.35

Technical Indicators

Market Signals
Indicator
CLPR
EQ
Relative Strength Index (RSI) 49.81 63.12
Support Level $3.31 $1.04
Resistance Level $3.48 $1.26
Average True Range (ATR) 0.09 0.20
MACD 0.02 0.06
Stochastic Oscillator 83.33 75.99

Price Performance

Historical Comparison
CLPR
EQ

About CLPR Clipper Realty Inc.

Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: